Markets
← Back to Stocks
REGN
REGENERON PHARMACEUTICALS
Health Care · Biotechnology
$737.24
-0.93%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
Regeneron extends Phase 3 Itepekimab program while maintaining Buy consensus on strong obesity treatment pipeline.
Regeneron closed at $756.91 and dropped $2.59 in after-hours trading on March 17. Company reported strong Q4 2025 earnings with 3% revenue growth and $11.44 adjusted EPS, with extended Phase 3 Itepekimab program in chronic sinus disease announced March 16. 24 analysts rate Buy with $819.54 average price target (9.86% upside), highlighting confidence in Dupixent and obesity treatment innovation.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$78.0B
P/E (TTM)17.8
Forward P/E14.0
Beta0.40
Div Yield51.00%
Prev Close$744.12
RSI (14-Day)
38Neutral
0305070100
52-Week Range
$476.49$737.24$821.11
From High-10.2%
From Low+54.7%
Moving Averages
50d SMA
$767.61-4.0%
200d SMA
$649.22+13.6%
Price between 50d and 200d. Testing 50d support.
Returns
1W
-1.3%
1M
-6.8%
3M
-1.1%
6M
+26.2%
1Y
+11.5%
YTD
-4.9%
Volume
Today12K
20d Avg604K
Ratio0.02x